低血糖治疗对阻塞性睡眠呼吸暂停患者的好处
Ruihan Lin1,2,3,4, Wenjie Yan1,2,3,5, Meng He1
1Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, China.
Sleep & breathing = Schlaf & Atmung
|March 15, 2024
概括
低血糖治疗显著降低了阻塞性睡眠呼吸暂停 (OSA) 患者的呼吸暂停-低血糖指数 (AHI). 糖共传输体2抑制剂 (SGLT2i) 在改善OSA指标方面表现特别强烈.
科学领域:
- 睡眠医学 睡眠医学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阻塞性睡眠呼吸暂停 (OSA) 经常与血糖异常有关.
- 了解睡眠障碍与代谢健康之间的相互作用至关重要.
研究的目的:
- 调查低血糖治疗对阻塞性睡眠呼吸暂停相关的关键指标的影响.
- 评估不同低血糖治疗对OSA严重性的有效性.
主要方法:
- 在主要数据库 (Web of Science,PubMed,Embase,Cochrane Library) 进行系统的文献搜索,截至2022年12月.
- 包括七项原始研究,重点是用低血糖药物治疗的OSA患者.
- 对呼吸暂停-呼吸暂停指数 (AHI) 和糖化血红蛋白A1c (HbA1c) 的治疗效应的元分析.
主要成果:
- 低血糖治疗导致AHI显著降低7.07/h (p=0.0001).
- 葡萄糖携带载体2抑制剂 (SGLT2i) 显示AHI显著下降 (-11.00/h,p<0.00001).
- 在HbA1c,爱普沃思睡眠度量,BMI和血压方面也观察到改善.
结论:
- 低血糖治疗对阻塞性睡眠呼吸暂停的患者提供了显著的益处.
- SGLT2 抑制剂代表了在患有血糖异常的患者中管理OSA的有前途的治疗选择.
- 需要进一步的研究,以充分阐明OSA和血糖控制之间的复杂关系.
相关概念视频
Hypoglycemia and Glucagon
259
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
259
Sleep Apnea
151
Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
The condition is more prevalent among...
151
Oral Hypoglycemic Agents: Biguanides and Glitazones
199
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
199
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
174
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
174
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
208
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
208
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154


